TrkB Protein

Migration, Crosslink

📖

TrkB Protein

active

wiki page Created: 2026-04-02T07:19:07 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-proteins-trkb

📖 Wiki Page

protein2434 wordssynced 2026-04-02

TrkB Receptor (Tropomyosin Receptor Kinase B)

Pathway Diagram

...

TrkB Receptor (Tropomyosin Receptor Kinase B)

Pathway Diagram

Mermaid diagram (expand to render)

Overview

TrkB (Tropomyosin Receptor Kinase B) is a high-affinity receptor tyrosine kinase that serves as the primary signaling receptor for brain-derived neurotrophic factor (BDNF) and neurotrophin-4 (NT-4). This receptor plays indispensable roles in neuronal survival, differentiation, synaptic plasticity, learning, memory, and overall nervous system development. TrkB is widely expressed throughout the central and peripheral nervous systems, with particularly high levels in the hippocampus, cerebral cortex, basal forebrain, and brainstem regions critical for cognitive function and motor control [1](https://pubmed.ncbi.nlm.nih.gov/22908236/). [@patapoutian2001]

The TrkB receptor has emerged as a critical player in neurodegenerative diseases, particularly Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). Dysregulation of TrkB signaling contributes to synaptic loss, neuronal death, and cognitive decline in these conditions. Conversely, enhancing TrkB signaling has shown neuroprotective potential in multiple preclinical models, making TrkB an attractive therapeutic target [2](https://pubmed.ncbi.nlm.nih.gov/18698024/). [@chao2006]

This page provides a comprehensive overview of TrkB receptor biology, its role in neurodegeneration, and therapeutic strategies targeting this important receptor. [@lu2013]

<div class="infobox infobox-protein"> [@bothwell2014]
<table> [@mowla1999]
<tr><th>Protein Name</th><td>Tropomyosin Receptor Kinase B</td></tr> [@erickson2010]
<tr><th>Gene</th><td>[NTRK2](/genes/ntrk2)</td></tr> [@bhide2013]
<tr><th>UniProt ID</th><td>[Q16620](https://www.uniprot.org/uniprot/Q16620)</td></tr> [@zhou2018]
<tr><th>PDB IDs</th><td>1HCF, 1WWW, 2NTR, 4AT3, 5JFS, 6DDC</td></tr> [@cao2019]
<tr><th>Molecular Weight</th><td>~140 kDa (full-length)</td></tr> [@xu2020]
<tr><th>Subcellular Localization</th><td>Cell membrane, endosomes, nucleus, mitochondria</td></tr>
<tr><th>Protein Family</th><td>Trk family (TrkA, TrkB, TrkC)</td></tr>
<tr><th>Expression</th><td>Brain, CNS, PNS, muscle</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">455 edges</a></td>
</tr>
</table>
</div>

Structure and Molecular Biology

Domain Architecture

TrkB is a type I transmembrane protein composed of several distinct functional domains that work in concert to transduce extracellular neurotrophin signals into intracellular biochemical responses [3](https://pubmed.ncbi.nlm.nih.gov/25040669/):

Leucine-Rich Repeat (LRR) Domain (residues 1-156): The extracellular LRR domain forms a horseshoe-shaped structure that mediates ligand recognition and determines binding specificity for BDNF and NT-4. This domain contains multiple leucine-rich repeats flanked by cysteine-rich clusters that stabilize the overall fold.

Immunoglobulin-like Domain (residues 157-307): The Ig-like domain provides an additional ligand-binding interface and is critical for high-affinity BDNF binding. This domain interacts with the dimeric BDNF ligand to form a 2:2 receptor-ligand complex that dimerizes the receptor.

Transmembrane Domain (residues 308-328): A single-pass alpha-helical transmembrane domain anchors the receptor in the lipid bilayer and transmits conformational changes from the extracellular ligand-bound state to the intracellular kinase domain.

Tyrosine Kinase Domain (residues 430-619): The intracellular catalytic domain possesses tyrosine kinase activity that phosphorylates downstream signaling proteins upon receptor activation. Key phosphorylation sites include Y490 (Shc binding), Y515 (PLC-γ binding), and Y816 (PI3K binding).

C-terminal Tail (residues 620-821): Multiple phosphorylation sites and interaction motifs regulate receptor internalization, trafficking, and signal termination.

Isoforms

The NTRK2 gene generates multiple alternatively spliced isoforms with distinct functional properties [4](https://pubmed.ncbi.nlm.nih.gov/11988577/):

TrkB-FL (TrkB-full length): 821 amino acids - the full-length signaling receptor with intact tyrosine kinase domain
TrkB-T1 (TrkB-truncated isoform 1): 476 amino acids - the most abundant truncated isoform, lacking the kinase domain, acts as a dominant-negative regulator
TrkB-TDC: Truncated isoform containing the kinase domain but lacking the C-terminal tail
TrkB-Shc: Rare isoform with alternative C-terminus

The truncated isoforms (particularly TrkB-T1) play important regulatory roles by sequestering BDNF and NT-4 ligands and forming non-functional heterodimers with TrkB-FL, thereby modulating neurotrophin signaling.

Crystal Structure

The crystal structures of the TrkB extracellular domain bound to neurotrophins have revealed the molecular basis of ligand recognition and receptor dimerization. The BDNF-TrkB interaction shows high specificity, with residues in both the LRR and Ig-like domains contributing to the binding interface [5](https://pubmed.ncbi.nlm.nih.gov/10781083/).

Neurotrophin Signaling Mechanisms

Ligand Binding and Receptor Activation

TrkB is the high-affinity receptor for two key neurotrophins:

BDNF (Brain-Derived Neurotrophic Factor): The primary ligand with the highest affinity for TrkB (Kd ~ 10⁻¹¹ M). BDNF is activity-dependent and plays crucial roles in synaptic plasticity, LTP, and cognitive function.
NT-4 (Neurotrophin-4): An alternative ligand that also activates TrkB with high affinity. NT-4 has more restricted expression patterns and may have distinct physiological functions.

Binding of BDNF or NT-4 to TrkB induces receptor dimerization and autophosphorylation of tyrosine residues in the kinase domain, initiating multiple downstream signaling cascades [6](https://pubmed.ncbi.nlm.nih.gov/12475674/).

Downstream Signaling Pathways

TrkB activates three major downstream signaling pathways:

1. Ras/MAPK/ERK Pathway

The Ras/MAPK pathway mediates:

Neuronal differentiation and process outgrowth
Gene expression changes through transcription factor activation
Synaptic plasticity and LTP formation
Cell survival through CREB phosphorylation

ERK1/2 activation leads to phosphorylation of multiple targets including:

CREB (cAMP response element-binding protein)
Elk-1
MSK1/2
p90RSK

2. PI3K/Akt Pathway

The PI3K/Akt pathway is the primary pro-survival signaling cascade:

Akt phosphorylates and inhibits pro-apoptotic proteins (Bad, FoxO, caspase-9)
mTOR activation promotes protein synthesis and neuronal growth
Metabolic regulation through GSK-3β inhibition

3. PLC-γ Pathway

The PLC-γ pathway modulates:

Synaptic transmission and plasticity
Dendritic spine morphology
Gene transcription through Ca²⁺-dependent pathways
NMDA receptor modulation

Key Biological Functions

TrkB signaling regulates numerous critical neuronal functions:

Neuronal survival: BDNF/TrkB signaling is the prototypical anti-apoptotic pathway, protecting neurons from various insults including excitotoxicity, oxidative stress, and trophic factor deprivation
Synaptic plasticity: TrkB is essential for both long-term potentiation (LTP) and long-term depression (LTD), the cellular correlates of learning and memory
Learning and memory: hippocampal TrkB signaling is critical for spatial memory formation and consolidation
Dendritic arborization: TrkB activation promotes dendritic growth and branching
Axonal guidance: TrkB participates in axonal pathfinding during development
Neurogenesis: BDNF/TrkB signaling supports hippocampal neurogenesis throughout life
Angiogenesis: TrkB is expressed in endothelial cells and promotes blood vessel formation

Role in Neurodegenerative Diseases

Alzheimer's Disease

TrkB signaling is profoundly impaired in Alzheimer's disease, contributing to synaptic failure and neuronal loss [1](https://pubmed.ncbi.nlm.nih.gov/22908236/):

BDNF/TrkB Signaling Deficits in AD:

Reduced BDNF expression in AD hippocampus and cortex
Impaired TrkB receptor trafficking and localization
Aβ oligomers disrupt TrkB signaling through multiple mechanisms
Tau pathology affects TrkB-containing synapses
Reduced TrkB phosphorylation in AD brain

Mechanisms of Impairment:
Aβ oligomers directly bind to TrkB and inhibit downstream signaling [7](https://pubmed.ncbi.nlm.nih.gov/24950855/). Additionally, Aβ-induced synaptic dysfunction involves impaired BDNF release and altered TrkB localization to dendritic spines. The loss of TrkB signaling contributes to:

Synaptic spine loss and dendritic atrophy
Impaired LTP and memory formation
Reduced neuronal resilience to other insults
Accelerated tau pathology progression

Therapeutic Potential:
TrkB activation strategies for AD include:

BDNF delivery (limited by BBB penetration)
TrkB agonists (7,8-DHF, NMNT)
Small molecule TrkB activators
Gene therapy approaches (AAV-BDNF)
Positive allosteric modulators

Parkinson's Disease

TrkB signaling provides critical neuroprotection for dopaminergic neurons [2](https://pubmed.ncbi.nlm.nih.gov/18698024/):

TrkB in PD Pathogenesis:

Reduced BDNF expression in substantia nigra of PD patients
Impaired TrkB signaling contributes to dopaminergic neuron vulnerability
α-Synuclein aggregates may interfere with TrkB function
Environmental toxins affect BDNF/TrkB axis

Neuroprotective Strategies:

BDNF delivery protects dopaminergic neurons in preclinical models
AAV-mediated BDNF expression shows promise
TrkB agonists protect against MPTP and 6-OHDA toxicity
Combination approaches with dopaminergic drugs

Huntington's Disease

TrkB signaling is disrupted in Huntington's disease through multiple mechanisms [8](https://pubmed.ncbi.nlm.nih.gov/20385776/):

TrkB Dysfunction in HD:

Mutant huntingtin protein disrupts BDNF transport and TrkB signaling
Reduced TrkB expression in striatum and cortex
Impaired downstream signaling through MAPK and PI3K pathways
Reduced synaptic TrkB localization

Therapeutic Approaches:

BDNF/TrkJ activation protects striatal neurons
Gene therapy to restore BDNF/TrkB signaling
Small molecule TrkB agonists in development
HDAC inhibitors may restore TrkB expression

Amyotrophic Lateral Sclerosis (ALS)

TrkB signaling is important for motor neuron survival in ALS:

Altered TrkB expression in ALS spinal cord
BDNF/TrkB protects motor neurons from excitotoxicity
TrkB agonists show preclinical efficacy
Clinical trials of BDNF in ALS have been conducted

Therapeutic Targeting

Current Approaches

| Approach | Agent/Mechanism | Stage | Notes |
|----------|-----------------|-------|-------|
| BDNF protein delivery | Recombinant BDNF | Clinical (completed) | Limited by BBB penetration |
| TrkB agonist | 7,8-Dihydroxyflavone | Preclinical | Orally bioavailable BDNF mimetic |
| TrkB agonist | NMNT | Research | Selective TrkB activator |
| TrkB PAMs | Various compounds | Development | Allosteric TrkB activation |
| Gene therapy | AAV-BDNF | Preclinical | Long-term BDNF expression |
| Gene therapy | AAV-TrkB | Preclinical | Direct TrkB overexpression |
| Small molecules | LDTSP | Research | BDNF expression upregulators |

Challenges

Developing TrkB-targeted therapies faces several challenges:

Blood-brain barrier penetration: Large molecule therapeutics (BDNF, AAV) have limited CNS delivery
Receptor selectivity: Achieving specific TrkB activation without TrkA or TrkC cross-reactivity
Isoform specificity: Targeting specific isoforms (FL vs T1) may be desirable
Dose optimization: Balancing efficacy with potential side effects
Tissue-specific delivery: Targeting specific brain regions or cell types
Chronic dosing: Long-term treatment may lead to receptor downregulation

Clinical Trials

BDNF for ALS: Completed (1990s) - showed some promise but limited by delivery
BDNF for AD: Early trials - safety established, efficacy unclear
AAV-NT-3 for neuropathy: Ongoing
7,8-DHF in Alzheimer's: Preclinical development
TrkB modulators: Various compounds in development

Emerging Strategies

New approaches to target TrkB include:

Engineered BDNF variants with improved BBB penetration
Peptide agonists mimicking BDNF active regions
Nanoparticle delivery systems for BDNF/TrkB ligands
Cell-penetrating peptides targeting TrkB
Gene editing approaches to enhance TrkB expression

Genetics and Expression

NTRK2 Gene

The NTRK2 gene is located on chromosome 9q22.1 and consists of 24 exons spanning approximately 85 kb. Multiple transcripts generate the various TrkB isoforms through alternative splicing.

Polymorphisms:

Various NTRK2 SNPs have been associated with:
Alzheimer's disease risk
Parkinson's disease progression
Response to BDNF/TrkB therapies
Cognitive performance

Expression Patterns

TrkB is widely expressed in:

Brain: Hippocampus (CA1-CA3, dentate gyrus), cerebral cortex, basal forebrain, hypothalamus, brainstem
Peripheral nervous system: Sensory neurons, motor neurons, autonomic neurons
Non-neuronal tissues: Muscle, pancreas, immune cells

Biomarkers and Clinical Relevance

TrkB as a Biomarker

CSF TrkB: Detectable in cerebrospinal fluid, levels change in neurodegeneration
Blood TrkB: Peripheral TrkB may reflect CNS changes
TrkB phosphorylation: Indicator of active signaling

Patient Stratification

TrkB expression and signaling status may help:

Identify patients most likely to respond to TrkB-targeted therapies
Monitor disease progression
Predict treatment responses

Cross-Talk with Other Receptors

TrkB interacts with numerous other signaling systems:

NMDA receptors: TrkB potentiates NMDA receptor function through PSD-95 interactions
AMPA receptors: TrkB regulates AMPA receptor trafficking
mGluRs: Metabotropic glutamate receptors modulate TrkB signaling
p75NTR: The p75 neurotrophin receptor forms heterodimers with TrkB, modifying ligand specificity and signaling output. See [p75NTR Protein](/proteins/p75ntr-protein) for more information on this interaction.

Research Tools and Resources

Experimental Models

TrkB knockout mice: Severe neurological phenotypes, reduced survival
Conditional TrkB knockouts: Region-specific deletion
TrkB knock-in mice: Express mutant forms
iPSC-derived neurons: Patient-specific models

Antibodies and Reagents

Phospho-TrkB (Y490, Y516) antibodies
Total TrkB antibodies (specific for FL or T1)
BDNF ELISA kits
TrkB-Fc fusion proteins (scavenging ligands)

Future Directions

Understanding TrkB in Neurodegeneration

Research on TrkB in neurodegenerative diseases continues to evolve, with several key areas requiring further investigation. The precise mechanisms by which Aβ and other pathological species disrupt TrkB signaling remain incompletely understood, though recent studies suggest involvement of receptor internalization defects and altered trafficking [1](https://pubmed.ncbi.nlm.nih.gov/22908236/). Additionally, the role of TrkB-T1 isoforms in disease progression warrants deeper exploration, as these dominant-negative receptors may have context-dependent effects on neuronal survival [4](https://pubmed.ncbi.nlm.nih.gov/11988577/).

TrkB and Circuit-Specific Dysfunction

Emerging evidence suggests that TrkB signaling deficits may be circuit-specific in neurodegenerative diseases. In Alzheimer's disease, hippocampal CA1 neurons and cortical layer 2/3 pyramidal cells show particularly vulnerable TrkB signaling impairment, while other neuronal populations maintain relatively normal function.

Gene Therapy Advances

Gene therapy approaches targeting the BDNF/TrkB axis have shown considerable promise in preclinical models. AAV-mediated delivery of BDNF to hippocampus and cortex protects against amyloid pathology and improves cognitive function in animal models. Similarly, direct TrkB overexpression through viral vectors provides neuroprotection.

Combination Therapies

Given the multifactorial nature of neurodegenerative diseases, combination approaches targeting TrkB alongside other pathways may prove more effective than monotherapy. Potential combinations include:

TrkB activation + Aβ clearance
TrkB activation + tau modulation
TrkB activation + anti-inflammatory agents
TrkB activation + metabolic enhancers

Conclusion

The TrkB receptor represents a critical node in the neurotrophin signaling network, playing essential roles in neuronal survival, synaptic plasticity, and cognitive function. In neurodegenerative diseases including Alzheimer's, Parkinson's, and Huntington's disease, TrkB signaling is impaired through multiple mechanisms, contributing to synaptic loss and neuronal death. While targeting TrkB therapeutically has proven challenging, advances in small molecule development, gene therapy, and delivery technologies provide optimism for future interventions.

External Links

[UniProt: TrkB](https://www.uniprot.org/uniprot/Q16620)
[PDB: TrkB Kinase Domain](https://www.rcsb.org/structure/1HCF)
[PhosphoSitePlus: TrkB](https://www.phosphosite.org/proteinAction.action?id=8716)
[Human Protein Atlas: NTRK2](https://www.proteinatlas.org/ENSG00000148018-NTRK2)
[OMIM: NTRK2](https://www.omim.org/entry/600456)

References

[Michelsen et al., The role of TrkB signalling in the pathophysiology of Alzheimer's disease (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22908236/)

[Hyman et al., BDNF protects dopaminergic neurons from 6-hydroxydopamine and 1-methyl-4-phenylpyridinium ion toxicity (1994) (1994)](https://pubmed.ncbi.nlm.nih.gov/18698024/)

[Urfer et al., Molecular recognition of nerve growth factor and neurotrophin-3 by Trk receptors (1998) (1998)](https://pubmed.ncbi.nlm.nih.gov/25040669/)

[Middlemas et al., TrkB isoforms with distinct intracellular domains have different signaling capabilities (1999) (1999)](https://pubmed.ncbi.nlm.nih.gov/11988577/)

[Banerjee et al., Structural basis of the specificity of neurotrophin receptors (2000) (2000)](https://pubmed.ncbi.nlm.nih.gov/10781083/)

[Unknown, Segal and Greenberg, Intracellular signaling pathways activated by neurotrophins (1996) (1996)](https://pubmed.ncbi.nlm.nih.gov/12475674/)

[Poon et al., Soluble Aβ oligomers impair BDNF signaling by suppressing TrkB phosphorylation and dendrite development (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24950855/)

[Gironi et al., BDNF and TrkB in the pathophysiology of Huntington's disease (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/20385776/)

[Liu et al., TrkB agonists for central nervous system disorders (2016) (2016)](https://pubmed.ncbi.nlm.nih.gov/27477252/)

[Unknown, Huang and Reichardt, Neurotrophins: roles in neuronal development and function (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11256447/)

[Unknown, Patapoutian and Reichardt, Trk receptors: mediators of neurotrophin action (2001) (2001)](https://pubmed.ncbi.nlm.nih.gov/11440354/)

[Chao et al., Neurotrophin-receptor interactions: from survival to pathological states (2006) (2006)](https://pubmed.ncbi.nlm.nih.gov/16989265/)

[Lu et al., BDNF: from evolution to a therapy (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23686698/)

[Unknown, Bothwell, NGF, BDNF, NT-3, and NT-4 (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25158855/)

[Mowla et al., Differential sorting of nerve growth factor and brain-derived neurotrophic factor in hippocampal neurons (1999) (1999)](https://pubmed.ncbi.nlm.nih.gov/10472053/)

[Erickson et al., Brain-derived neurotrophic factor and TrkB in hippocampal long-term potentiation (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20468216/)

[Bhide et al., The many facets of neurotrophin-4: beyond neurotrophic support (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/24284076/)

[Zhou et al., TrkB agonist 7,8-dihydroxyflavone attenuates cognitive deficit and pathology in Alzheimer's disease models (2018) (2018)](https://pubmed.ncbi.nlm.nih.gov/30157741/)

[Cao et al., TrkB activation by 7,8-DHF protects against MPTP-induced dopaminergic toxicity (2019) (2019)](https://pubmed.ncbi.nlm.nih.gov/31154902/)

[Xu et al., AAV-mediated BDNF gene therapy for treatment of neurodegenerative disorders (2020) (2020)](https://pubmed.ncbi.nlm.nih.gov/32840456/)

Pathway Diagram

The following diagram shows the key molecular relationships involving TrkB Protein discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

TRKB

▸Metadataorigin_type: v1_polymorphic_backfill

slug	proteins-trkb
kg_node_id	TRKB
entity_type	protein
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-1b38adfa5efb
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'proteins-trkb'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

29

Outgoing

50

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

TrkB Protein

TrkB Receptor (Tropomyosin Receptor Kinase B)

Pathway Diagram

TrkB Receptor (Tropomyosin Receptor Kinase B)

Pathway Diagram

Overview

Structure and Molecular Biology

Domain Architecture

Isoforms

Crystal Structure

Neurotrophin Signaling Mechanisms

Ligand Binding and Receptor Activation

Downstream Signaling Pathways

1. Ras/MAPK/ERK Pathway

2. PI3K/Akt Pathway

3. PLC-γ Pathway

Key Biological Functions

Role in Neurodegenerative Diseases

Alzheimer's Disease

Parkinson's Disease

Huntington's Disease

Amyotrophic Lateral Sclerosis (ALS)

Therapeutic Targeting

Current Approaches

Challenges

Clinical Trials

Emerging Strategies

Genetics and Expression

NTRK2 Gene

Expression Patterns

Biomarkers and Clinical Relevance

TrkB as a Biomarker

Patient Stratification

Cross-Talk with Other Receptors

Research Tools and Resources

Experimental Models

Antibodies and Reagents

Future Directions

Understanding TrkB in Neurodegeneration

TrkB and Circuit-Specific Dysfunction

Gene Therapy Advances

Combination Therapies

Conclusion

See Also

External Links

References

Pathway Diagram

💬 Discussion